These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 15500133

  • 21. Other immunosuppressive agents for focal segmental glomerulosclerosis.
    Ponticelli C, Passerini P.
    Semin Nephrol; 2003 Mar; 23(2):242-8. PubMed ID: 12704585
    [Abstract] [Full Text] [Related]

  • 22. [Mycophenolate mofetil restores renal function and spares steroids during idiopathic nephrotic syndrome in children. A cohort study].
    Cailliez M, Bruno D, Daniel L, Afaneti M, Bérard E, Sarles J, Tsimaratos M.
    Nephrol Ther; 2008 Feb; 4(1):15-20. PubMed ID: 18096455
    [Abstract] [Full Text] [Related]

  • 23. Management of childhood onset nephrotic syndrome.
    Gipson DS, Massengill SF, Yao L, Nagaraj S, Smoyer WE, Mahan JD, Wigfall D, Miles P, Powell L, Lin JJ, Trachtman H, Greenbaum LA.
    Pediatrics; 2009 Aug; 124(2):747-57. PubMed ID: 19651590
    [Abstract] [Full Text] [Related]

  • 24. Immunosuppressive therapy for autoimmune bullous diseases.
    Meurer M.
    Clin Dermatol; 2012 Aug; 30(1):78-83. PubMed ID: 22137230
    [Abstract] [Full Text] [Related]

  • 25. Mizoribine versus mycophenolate mofetil in combination therapy with tacrolimus for de novo kidney transplantation: evaluation of efficacy and safety.
    Ju MK, Huh KH, Park KT, Kim SJ, Cho BH, Kim CD, So BJ, Kang CM, Lee S, Joo DJ, Kim YS.
    Transplant Proc; 2013 May; 45(4):1481-6. PubMed ID: 23726602
    [Abstract] [Full Text] [Related]

  • 26. Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil.
    Chandra M, Susin M, Abitbol C.
    Pediatr Nephrol; 2000 Mar; 14(3):224-6. PubMed ID: 10752763
    [Abstract] [Full Text] [Related]

  • 27. [Treatment guidelines for the idiopathic nephrotic syndrome in children].
    Yoshikawa N, Honda M, Sekine K, Nakanishi K, Iijima I, Ootomo Y, Ikeda M, Wada N, Nakamura H, Sako M, Japanese Society of Nephrology Committee for Development of Guidelines for Drug Therapy for Nephrotic Syndrome in Children.
    Nihon Jinzo Gakkai Shi; 2005 Mar; 47(7):790-803. PubMed ID: 16296409
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Maintenance therapy with single-daily, high-dose mizoribine after cyclophosphamide therapy for prepubertal boys with severe steroid-dependent nephrotic syndrome.
    Fujinaga S, Endo A, Watanabe T, Hirano D, Ohtomo Y, Shimizu T, Kaneko K.
    Clin Nephrol; 2012 Sep; 78(3):251-2. PubMed ID: 22541687
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Recent clinical trials in lupus nephritis.
    Ward MM.
    Rheum Dis Clin North Am; 2014 Aug; 40(3):519-35, ix. PubMed ID: 25034160
    [Abstract] [Full Text] [Related]

  • 33. Rescue immunosuppressive therapies in living-related renal allotransplant: a long-term prospective randomized evaluation.
    Bakr MA, Gheith OA, Ismael AM, Baz ME, Shehab El-Dein AB, Ghoneim MA.
    Exp Clin Transplant; 2008 Mar; 6(1):48-53. PubMed ID: 18405245
    [Abstract] [Full Text] [Related]

  • 34. A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey).
    Shibasaki T, Koyama A, Hishida A, Muso E, Osawa G, Yamabe H, Shiiki H, Makino H, Sato H, Ishikawa I, Maeda K, Tomita K, Arakawa M, Ishida M, Sato M, Nagase M, Kashihara N, Yorioka N, Koike T, Saito T, Harada T, Mitarai T, Sugisaki T, Nagasawa T, Tomino Y, Nojima Y, Kobayashi Y, Sakai O.
    Clin Exp Nephrol; 2004 Jun; 8(2):117-26. PubMed ID: 15235928
    [Abstract] [Full Text] [Related]

  • 35. Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome.
    Kawasaki Y, Hosoya M, Kobayashi S, Ohara S, Onishi N, Takahashi A, Isome M, Suzuki H.
    Nephrol Dial Transplant; 2005 Oct; 20(10):2243-7. PubMed ID: 16030039
    [Abstract] [Full Text] [Related]

  • 36. [Mycophenolate mofetil in the treatment of primary nephrotic syndrome].
    Zhao M, Chen X, Chen Y, Liu Z, Liu Y, Lu F, Zhang Y, Wang H.
    Zhonghua Yi Xue Za Zhi; 2001 May 10; 81(9):528-31. PubMed ID: 11809115
    [Abstract] [Full Text] [Related]

  • 37. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression.
    Chan TM, Li FK, Hao WK, Chan KW, Lui SL, Tang S, Lai KN.
    Lupus; 1999 May 10; 8(7):545-51. PubMed ID: 10483033
    [Abstract] [Full Text] [Related]

  • 38. Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/azathioprine.
    Vacher-Coponat H, Brunet C, Moal V, Loundou A, Bonnet E, Lyonnet L, Ravet S, Sampol-Manos E, Sampol J, Berland Y, George FD, Paul P.
    Transplantation; 2006 Aug 27; 82(4):558-66. PubMed ID: 16926601
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of combined cyclosporin A and mycophenolate mofetil therapy in patients with cyclosporin-resistant focal segmental glomerulosclerosis.
    Segarra Medrano A, Vila Presas J, Pou Clavé L, Majó Masferrer J, Camps Doménech J.
    Nefrologia; 2011 Aug 27; 31(3):286-91. PubMed ID: 21468162
    [Abstract] [Full Text] [Related]

  • 40. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome.
    Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB.
    Pediatr Nephrol; 2003 Aug 27; 18(8):833-7. PubMed ID: 12774223
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.